The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.
Dana Shelton Thompson
No relevant relationships to disclose
B. Stephens Dudley
No relevant relationships to disclose
John A. Bismayer
No relevant relationships to disclose
Victor G. Gian
No relevant relationships to disclose
William McIver Merritt
No relevant relationships to disclose
Robert C. Whorf
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose